SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses

Continuous emergence of SARS-CoV-2 variants of concern (VOCs) is fueling the COVID-19 pandemic. Omicron (B.1.1.529) rapidly spread worldwide. The large number of mutations in its Spike raise concerns about a major antigenic drift that could significantly decrease vaccine efficacy and infection-induced immunity. A long interval between BNT162b2 mRNA doses elicits antibodies that efficiently recognize Spikes from different VOCs. Here, we evaluate the recognition of Omicron Spike by plasma from a cohort of SARS-CoV-2 naive and previously infected individuals who received their BNT162b2 mRNA vaccine 16 weeks apart. Omicron Spike is recognized less efficiently than D614G, Alpha, Beta, Gamma, and Delta Spikes. We compare with plasma activity from participants receiving a short (4 weeks) interval regimen. Plasma from individuals of the long-interval cohort recognize and neutralize better the Omicron Spike compared with those who received a short interval. Whether this difference confers any clinical benefit against Omicron remains unknown.
Auteurs (Zotero)
Chatterjee, Debashree; Tauzin, Alexandra; Marchitto, Lorie; Gong, Shang Yu; Boutin, Marianne; Bourassa, Catherine; Beaudoin-Bussières, Guillaume; Bo, Yuxia; Ding, Shilei; Laumaea, Annemarie; Vézina, Dani; Perreault, Josée; Gokool, Laurie; Morrisseau, Chantal; Arlotto, Pascale; Fournier, Éric; Guilbault, Aurélie; Delisle, Benjamin; Levade, Inès; Goyette, Guillaume; Gendron-Lepage, Gabrielle; Medjahed, Halima; De Serres, Gaston; Tremblay, Cécile; Martel-Laferrière, Valérie; Kaufmann, Daniel E.; Bazin, Renée; Prévost, Jérémie; Moreira, Sandrine; Richard, Jonathan; Côté, Marceline; Finzi, Andrés
Date de publication (Zotero)
février, 2022